Affiliation:
1. Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
2. The first Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University
3. The Second Affiliated Hospital of Fujian Medical University
Abstract
Abstract
Background
In this study, we aimed to evaluate the real-world efficacy and safety of camrelizumab and identify clinicolaboratory factors that predict treatment outcomes in patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) receiving camrelizumab.
Methods
Herein, 174 patients with unresectable advanced, recurrent, or metastatic ESCC treated with camrelizumab monotherapy (n = 30), camrelizumab + chemotherapy (CT; n = 91), and camrelizumab + radiotherapy (RT; n = 53) between October 1, 2019 and October 1, 2022 were included.
Results
The median follow-up time was 20 months (range, 1–34 months). The median progression-free survival (PFS) and overall survival (OS) of the whole cohort were 8 months [95% confidence interval (CI), 6.5–9.5 months] and 14 months (95% CI, 11.2–16.8 months), respectively. After multivariate analysis, receiving > 4 cycles of camrelizumab and having a good lung immune prognostic index (LIPI) were identified as independent predictors of better PFS and OS. The objective response rate of patients in the camrelizumab monotherapy group, camrelizumab + CT group, and camrelizumab + RT group was 46.2%, 47.1%, and 37.3%, respectively. The treatment-related adverse events (AEs) of grade 3 or higher were reported in 67 patients (38.5%). The most common treatment-related AEs were decreased neutrophil count (23.0%), decreased white blood cell count (19.5%), anemia (7.5%), and pneumonitis (4.6%). One patient (0.6%) died from a treatment-related AE of immune checkpoint inhibitor-induced myocarditis.
Conclusion
Camrelizumab was safe and effective as both monotherapy and part of a combination therapy. Longer PFS and OS were associated with receiving > 4 cycles of camrelizumab and having a good LIPI. LIPI can be used as a prognostic biomarker for ESCC patients receiving camrelizumab + RT.
Publisher
Research Square Platform LLC
Reference35 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;Cancer J Clin,2021
2. Global incidence, mortality, and burden of esophageal cancer, and its correlation with SDI, metabolic risks, fasting plasma glucose, LDL cholesterol, and body mass index: An ecological study;A AMM;Health Sci Rep
3. Epidemiologic differences in esophageal cancer between Asian and Western populations;Zhang HZ;Chin J Cancer,2012
4. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER);M MMM;Annals of oncology: official journal of the European Society for Medical Oncology,2020
5. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology;Ajani JA;J Natl Compr Cancer Network: JNCCN,2019